Re: Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States
- 25 July 2025
- journal article
- Published by Elsevier in International Journal of Drug Policy
- Vol. 143, 104933
Abstract
No abstract availableFunding Information
- Indivior Inc
This publication has 10 references indexed in Scilit:
- Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United StatesInternational Journal of Drug Policy, 2025
- 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trialInternational Journal of Drug Policy, 2024
- Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claimsAddiction Science & Clinical Practice, 2024
- Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trialeClinicalMedicine, 2023
- Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use DisorderThe Journal of Clinical Psychiatry, 2022
- Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependenceInternational Journal of Drug Policy, 2022
- Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care settingJournal of Substance Abuse Treatment, 2021
- Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB studyBMJ Open, 2020
- Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrolleesJournal of Substance Abuse Treatment, 2018
- Long-term retention in Office Based Opioid Treatment with buprenorphineJournal of Substance Abuse Treatment, 2017